Oncology based Molecular Diagnostics Market Report

Oncology based Molecular Diagnostics Market Analysis By Type (Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, Blood Cancer, Kidney Cancer) By Product (Instruments, Reagents), By Test Location, By Technology (PCR, Multiplex PCR, In Situ Hybridization, Isothermal Nucleic Acid Amplification Technology (INAAT), Chips & Microarrays, Mass Spectrometry, Sequencing, Transcription Mediated Amplification) And Segment Forecasts To 2022

  • Published Date: Jan, 2016
  • Base Year for Estimate: 2015
  • Report ID: 978-1-68038-699-8
  • Format: Electronic (PDF)
  • Historical Data: 2013-2015
  • Number of Pages: 139

Market segmentation

  • Global Oncology Based Molecular Diagnostics Market Type Outlook (Revenue, USD Million, 2015 - 2022)
    • Breast cancer
    • Prostate cancer
    • Colorectal cancer
    • Cervical cancer
    • Liver cancer
    • Lung cancer
    • Blood cancer
    • Kidney cancer
    • Others
  • Global Oncology Based Molecular Diagnostics Market Product Outlook (Revenue, USD Million, 2015 - 2022)
    • Instruments
    • Reagents
    • Others
  • Global Oncology Based Molecular Diagnostics Market Test Location Outlook (Revenue, USD Million, 2015 - 2022)
    • Clinics and other establishments
    • Point of Care
  • Global Molecular Diagnostics Market Technology Outlook (Revenue, USD Million, 2015 - 2022)
    • PCR
      • Multiplex
      • Others
    • In Situ Hybridization
    • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Chips and microarrays
    • Mass spectrometry
    • Sequencing
    • Transcription Mediated Amplification
    • Others
  • Oncology based molecular diagnostics Market Regional Outlook (Revenue, USD Million, 2015 - 2022)
    •  North America
      •  The U.S.
        • U.S. Type Outlook (Revenue, USD Million, 2012 - 2022)
          • Breast cancer
          • Prostate cancer
          • Colorectal cancer
          • Cervical cancer
          • Liver cancer
          • Lung cancer
          • Blood cancer
          • Kidney cancer
          • Others
        • U.S. Product Outlook (Revenue, USD Million, 2012 - 2022)
          • Instruments
          • Reagents
          • Others
        • U.S. Test Location Outlook (Revenue, USD Million, 2012 - 2022)
          • Clinics and other establishments
          • Point of Care
        • U.S. Technology Outlook (Revenue, USD Million, 2012 - 2022)
          • PCR
            • Multiplex
            • Others
          • In Situ Hybridization
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
          • Chips and microarrays
          • Mass spectrometry
          • Sequencing
          • Transcription Mediated Amplification
          • Others
      • Canada
        • Canada. Type Outlook (Revenue, USD Million, 2012 - 2022)
          • Breast cancer
          • Prostate cancer
          • Colorectal cancer
          • Cervical cancer
          • Liver cancer
          • Lung cancer
          • Blood cancer
          • Kidney cancer
          • Others
        • Canada Product Outlook (Revenue, USD Million, 2012 - 2022)
          • Instruments
          • Reagents
          • Others
        • Canada Test Location Outlook (Revenue, USD Million, 2012 - 2022)
          • Clinics and other establishments
          • Point of Care
        • Canada. Technology Outlook (Revenue, USD Million, 2012 - 2022)
          • PCR
            • Multiplex
            • Others
          • In Situ Hybridization
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
          • Chips and microarrays
          • Mass spectrometry
          • Sequencing
          • Transcription Mediated Amplification
          • Others
    • Europe
      • UK
        • UK Type Outlook (Revenue, USD Million, 2012 - 2022)
          • Breast cancer
          • Prostate cancer
          • Colorectal cancer
          • Cervical cancer
          • Liver cancer
          • Lung cancer
          • Blood cancer
          • Kidney cancer
          • Others
        • UK Product Outlook (Revenue, USD Million, 2012 - 2022)
          • Instruments
          • Reagents
          • Others
        • UK Test Location Outlook (Revenue, USD Million, 2012 - 2022)
          • Clinics and other establishments
          • Point of Care
        • UK. Technology Outlook (Revenue, USD Million, 2012 - 2022)
          • PCR
            • Multiplex
            • Others
          • In Situ Hybridization
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
          • Chips and microarrays
          • Mass spectrometry
          • Sequencing
          • Transcription Mediated Amplification
          • Others
      • Germany
        • Germany Type Outlook (Revenue, USD Million, 2012 - 2022)
          • Breast cancer
          • Prostate cancer
          • Colorectal cancer
          • Cervical cancer
          • Liver cancer
          • Lung cancer
          • Blood cancer
          • Kidney cancer
          • Others
        • Germany Product Outlook (Revenue, USD Million, 2012 - 2022)
          • Instruments
          • Reagents
          • Others
        • Germany Test Location Outlook (Revenue, USD Million, 2012 - 2022)
          • Clinics and other establishments
          • Point of Care
        • Germany Technology Outlook (Revenue, USD Million, 2012 - 2022)
          • PCR
            • Multiplex
            • Others
          • In Situ Hybridization
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
          • Chips and microarrays
          • Mass spectrometry
          • Sequencing
          • Transcription Mediated Amplification
          • Others
      • France
        • France Type Outlook (Revenue, USD Million, 2012 - 2022)
          • Breast cancer
          • Prostate cancer
          • Colorectal cancer
          • Cervical cancer
          • Liver cancer
          • Lung cancer
          • Blood cancer
          • Kidney cancer
          • Others
        • France Product Outlook (Revenue, USD Million, 2012 - 2022)
          • Instruments
          • Reagents
          • Others
        • France Test Location Outlook (Revenue, USD Million, 2012 - 2022)
          • Clinics and other establishments
          • Point of Care
        • France Technology Outlook (Revenue, USD Million, 2012 - 2022)
          • PCR
            • Multiplex
            • Others
          • In Situ Hybridization
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
          • Chips and microarrays
          • Mass spectrometry
          • Sequencing
          • Transcription Mediated Amplification
          • Others
      • Spain
        • Spain Type Outlook (Revenue, USD Million, 2012 - 2022)
          • Breast cancer
          • Prostate cancer
          • Colorectal cancer
          • Cervical cancer
          • Liver cancer
          • Lung cancer
          • Blood cancer
          • Kidney cancer
          • Others
        • Spain Product Outlook (Revenue, USD Million, 2012 - 2022)
          • Instruments
          • Reagents
          • Others
        • Spain Test Location Outlook (Revenue, USD Million, 2012 - 2022)
          • Clinics and other establishments
          • Point of Care
        • Spain Technology Outlook (Revenue, USD Million, 2012 - 2022)
          • PCR
            • Multiplex
            • Others
          • In Situ Hybridization
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
          • Chips and microarrays
          • Mass spectrometry
          • Sequencing
          • Transcription Mediated Amplification
          • Others
      • Italy
        • Italy Type Outlook (Revenue, USD Million, 2012 - 2022)
          • Breast cancer
          • Prostate cancer
          • Colorectal cancer
          • Cervical cancer
          • Liver cancer
          • Lung cancer
          • Blood cancer
          • Kidney cancer
          • Others
        • Italy Product Outlook (Revenue, USD Million, 2012 - 2022)
          • Instruments
          • Reagents
          • Others
        • Italy Test Location Outlook (Revenue, USD Million, 2012 - 2022)
          • Clinics and other establishments
          • Point of Care
        • Italy Technology Outlook (Revenue, USD Million, 2012 - 2022)
          • PCR
            • Multiplex
            • Others
          • In Situ Hybridization
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
          • Chips and microarrays
          • Mass spectrometry
          • Sequencing
          • Transcription Mediated Amplification
          • Others
    • Asia Pacific
      • Japan
        • Japan Type Outlook (Revenue, USD Million, 2012 - 2022)
          • Breast cancer
          • Prostate cancer
          • Colorectal cancer
          • Cervical cancer
          • Liver cancer
          • Lung cancer
          • Blood cancer
          • Kidney cancer
          • Others
        • Japan Product Outlook (Revenue, USD Million, 2012 - 2022)
          • Instruments
          • Reagents
          • Others
        • Japan Test Location Outlook (Revenue, USD Million, 2012 - 2022)
          • Clinics and other establishments
          • Point of Care
        • Japan Technology Outlook (Revenue, USD Million, 2012 - 2022)
          • PCR
            • Multiplex
            • Others
          • In Situ Hybridization
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
          • Chips and microarrays
          • Mass spectrometry
          • Sequencing
          • Transcription Mediated Amplification
          • Others
      • China
        • China Type Outlook (Revenue, USD Million, 2012 - 2022)
          • Breast cancer
          • Prostate cancer
          • Colorectal cancer
          • Cervical cancer
          • Liver cancer
          • Lung cancer
          • Blood cancer
          • Kidney cancer
          • Others
        • China Product Outlook (Revenue, USD Million, 2012 - 2022)
          • Instruments
          • Reagents
          • Others
        • China Test Location Outlook (Revenue, USD Million, 2012 - 2022)
          • Clinics and other establishments
          • Point of Care
        • China Technology Outlook (Revenue, USD Million, 2012 - 2022)
          • PCR
            • Multiplex
            • Others
          • In Situ Hybridization
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
          • Chips and microarrays
          • Mass spectrometry
          • Sequencing
          • Transcription Mediated Amplification
          • Others
      • India
        • India Type Outlook (Revenue, USD Million, 2012 - 2022)
          • Breast cancer
          • Prostate cancer
          • Colorectal cancer
          • Cervical cancer
          • Liver cancer
          • Lung cancer
          • Blood cancer
          • Kidney cancer
          • Others
        • India Product Outlook (Revenue, USD Million, 2012 - 2022)
          • Instruments
          • Reagents
          • Others
        • India Test Location Outlook (Revenue, USD Million, 2012 - 2022)
          • Clinics and other establishments
          • Point of Care
        • India Technology Outlook (Revenue, USD Million, 2012 - 2022)
          • PCR
            • Multiplex
            • Others
          • In Situ Hybridization
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
          • Chips and microarrays
          • Mass spectrometry
          • Sequencing
          • Transcription Mediated Amplification
          • Others
      • Australia
        • Australia Type Outlook (Revenue, USD Million, 2012 - 2022)
          • Breast cancer
          • Prostate cancer
          • Colorectal cancer
          • Cervical cancer
          • Liver cancer
          • Lung cancer
          • Blood cancer
          • Kidney cancer
          • Others
        • Australia Product Outlook (Revenue, USD Million, 2012 - 2022)
          • Instruments
          • Reagents
          • Others
        • Australia Test Location Outlook (Revenue, USD Million, 2012 - 2022)
          • Clinics and other establishments
          • Point of Care
        • Australia Technology Outlook (Revenue, USD Million, 2012 - 2022)
          • PCR
            • Multiplex
            • Others
          • In Situ Hybridization
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
          • Chips and microarrays
          • Mass spectrometry
          • Sequencing
          • Transcription Mediated Amplification
          • Others
      • New Zealand
        • New Zealand Type Outlook (Revenue, USD Million, 2012 - 2022)
          • Breast cancer
          • Prostate cancer
          • Colorectal cancer
          • Cervical cancer
          • Liver cancer
          • Lung cancer
          • Blood cancer
          • Kidney cancer
          • Others
        • New Zealand Product Outlook (Revenue, USD Million, 2012 - 2022)
          • Instruments
          • Reagents
          • Others
        • New Zealand Test Location Outlook (Revenue, USD Million, 2012 - 2022)
          • Clinics and other establishments
          • Point of Care
        • New Zealand Technology Outlook (Revenue, USD Million, 2012 - 2022)
          • PCR
            • Multiplex
            • Others
          • In Situ Hybridization
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
          • Chips and microarrays
          • Mass spectrometry
          • Sequencing
          • Transcription Mediated Amplification
          • Others
    • Latin America
      • Brazil
        • Brazil Type Outlook (Revenue, USD Million, 2012 - 2022)
          • Breast cancer
          • Prostate cancer
          • Colorectal cancer
          • Cervical cancer
          • Liver cancer
          • Lung cancer
          • Blood cancer
          • Kidney cancer
          • Others
        • Brazil Product Outlook (Revenue, USD Million, 2012 - 2022)
          • Instruments
          • Reagents
          • Others
        • Brazil Test Location Outlook (Revenue, USD Million, 2012 - 2022)
          • Clinics and other establishments
          • Point of Care
        • Brazil Technology Outlook (Revenue, USD Million, 2012 - 2022)
          • PCR
            • Multiplex
            • Others
          • In Situ Hybridization
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
          • Chips and microarrays
          • Mass spectrometry
          • Sequencing
          • Transcription Mediated Amplification
          • Others
      • Mexico
        • Mexico Type Outlook (Revenue, USD Million, 2012 - 2022)
          • Breast cancer
          • Prostate cancer
          • Colorectal cancer
          • Cervical cancer
          • Liver cancer
          • Lung cancer
          • Blood cancer
          • Kidney cancer
          • Others
        • Mexico Product Outlook (Revenue, USD Million, 2012 - 2022)
          • Instruments
          • Reagents
          • Others
        • Mexico Test Location Outlook (Revenue, USD Million, 2012 - 2022)
          • Clinics and other establishments
          • Point of Care
        • Mexico Technology Outlook (Revenue, USD Million, 2012 - 2022)
          • PCR
            • Multiplex
            • Others
          • In Situ Hybridization
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
          • Chips and microarrays
          • Mass spectrometry
          • Sequencing
          • Transcription Mediated Amplification
          • Others
      • Colombia
        • Colombia Type Outlook (Revenue, USD Million, 2012 - 2022)
          • Breast cancer
          • Prostate cancer
          • Colorectal cancer
          • Cervical cancer
          • Liver cancer
          • Lung cancer
          • Blood cancer
          • Kidney cancer
          • Others
        • Colombia Product Outlook (Revenue, USD Million, 2012 - 2022)
          • Instruments
          • Reagents
          • Others
          • Colombia Test Location Outlook (Revenue, USD Million, 2012 - 2022)
          • Clinics and other establishments
          • Point of Care
        • Colombia Technology Outlook (Revenue, USD Million, 2012 - 2022)
          • PCR
            • Multiplex
            • Others
          • In Situ Hybridization
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
          • Chips and microarrays
          • Mass spectrometry
          • Sequencing
          • Transcription Mediated Amplification
          • Others
    • MEA
      • South Africa
        • South Africa Type Outlook (Revenue, USD Million, 2012 - 2022)
          • Breast cancer
          • Prostate cancer
          • Colorectal cancer
          • Cervical cancer
          • Liver cancer
          • Lung cancer
          • Blood cancer
          • Kidney cancer
          • Others
        • South Africa Product Outlook (Revenue, USD Million, 2012 - 2022)
          • Instruments
          • Reagents
          • Others
          • South Africa Test Location Outlook (Revenue, USD Million, 2012 - 2022)
          • Clinics and other establishments
          • Point of Care
        • South Africa Technology Outlook (Revenue, USD Million, 2012 - 2022)
          • PCR
            • Multiplex
            • Others
          • In Situ Hybridization
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
          • Chips and microarrays
          • Mass spectrometry
          • Sequencing
          • Transcription Mediated Amplification
          • Others
      • South Arabia
        • South Arabia Type Outlook (Revenue, USD Million, 2012 - 2022)
          • Breast cancer
          • Prostate cancer
          • Colorectal cancer
          • Cervical cancer
          • Liver cancer
          • Lung cancer
          • Blood cancer
          • Kidney cancer
          • Others
        • South Arabia Product Outlook (Revenue, USD Million, 2012 - 2022)
          • Instruments
          • Reagents
          • Others
        • South Arabia Test Location Outlook (Revenue, USD Million, 2012 - 2022)
          • Clinics and other establishments
          • Point of Care
        • South Arabia Technology Outlook (Revenue, USD Million, 2012 - 2022)
          • PCR
            • Multiplex
            • Others
          • In Situ Hybridization
          • Isothermal Nucleic Acid Amplification Technology (INAAT)
          • Chips and microarrays
          • Mass spectrometry
          • Sequencing
          • Transcription Mediated Amplification
          • Others 

Report Content

Qualitative Analysis

  • Industry overview
  • Industry trends
  • Market drivers and restraints
  • Market size
  • Growth prospects
  • Porter’s analysis
  • PESTEL analysis
  • Key market opportunities prioritized
  • Competitive landscape
    • Company overview
    • Financial performance
    • Product benchmarking
    • Latest strategic developments

Quantitative Analysis

  • Market size, estimates, and forecast from 2012 to 2022
  • Revenue estimates for type up to 2022
  • Regional market size and forecast for type up to 2022
  • Revenue estimates for product up to 2022
  • Regional market size and forecast for product up to 2022
  • Revenue estimates for test location up to 2022
  • Regional market size and forecast for test location up to 2022
  • Revenue estimates for technology up to 2022
  • Regional market size and forecast for technology up to 2022
  • Regional market size and forecast for test up to 2022
  • Company financial performance
What questions do you have? Get quick response from our industry experts. Request a Free Consultation
gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.